A decrease in miR-215 levels is correlated with an increase in KDM1B levels in enzalutamide-resistant prostate cancer cells that promotes AR-dependent AGR2 transcription and regulates the sensitivity to AR-targeted therapy [45]. This evidence concerns the gene KDM1B and Familial prostate cancer.